Incidence and risk factors for invasive pneumococcal disease in HIV-positive individuals in the era of highly active antiretroviral therapy

Abstract

Invasive pneumococcal diseases (IPDs) remain a significant cause of morbidity and mortality in human immunodeficiency virus (HIV)-positive individuals despite the widespread use of highly active antiretroviral therapy (HAART) and availability of pneumococcal vaccines. The aim of this study was to measure temporal trends in incidence and risk factors for IPD (defined as culture of Streptococcus pneumoniae from blood, cerebrospinal fluid or both) in a cohort of HIV-positive patients attending an ambulatory HIV care centre in Dublin, Ireland over a 10-year period 2006–2015. Incidence of IPD was determined as events per 100,000 person-years’ follow-up. Poisson regression was used to assess linear trend in incidence over time. A nested case–control study (four controls per case) was undertaken to assess risk factors for IPD. Forty-seven episodes of IPD were identified in 42 HIV-positive individuals (median [IQR] age 38 years [33–43], 69% male, 86% injecting drug users (IDUs), median CD4 T-cell count 213 cells/mm³) over 16,008 person-years’ follow-up (overall incidence rate 293/100,000 person-years). Three patients had two episodes and one patient had three episodes of IPD during the study period. The overall case fatality rate was 15% (95% confidence interval [CI] 4–24%). The incidence of IPD per 100,000 person-years decreased from 728 (95% CI, 455–1002), to 242 (95% CI, 120–365) to 82 (95% CI, 40–154) in calendar periods 2006–2008, 2009–2012 and 2013–2015, respectively (p < 0.01 for linear trend). Older age (p = 0.02), male gender (p = 0.05), detectable HIV viral load (p < 0.01) and non-receipt of pneumococcal vaccine (p = 0.03) were associated with IPD while IDU as risk of acquisition of HIV was of borderline significance (p = 0.06). HIV-positive individuals remain at greater risk of IPD compared to the general population. Pneumococcal vaccine should be seen as a priority to ensure optimal protection for HIV-positive patients.

Keywords

Invasive pneumococcal disease human immunodeficiency virus pneumococcal vaccine

Get full access to this article

View all access options for this article.

References

Yin

Waight

Miller

et al . Invasive pneumococcal disease among HIV-positive individuals, 2000–2009. AIDS 2012; 26: 87–94.

Janoff

Breiman

Daley

et al . Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 1992; 117: 314–324.

Jones

Huebner

Khoosal

et al . The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. AIDS 1998; 12: 2177–2184.

French

Nakiyingi

Carpenter

et al . 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355: 2106–2111.

McEllistrem

Mendelsohn

Pass

et al . Recurrent invasive pneumococcal disease in individuals with human immunodeficiency virus infection. J Infect Dis 2002; 185: 1364–1368.

Titanji

De Milito

Cagigi

et al . Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006; 108: 1580–1587.

Hart

Steel

Clark

Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol 2007; 178: 8212–8220.

Feikin

Feldman

Schuchat

et al.

Global strategies to prevent bacterial pneumonia in adults with HIV disease.

Lancet Infect Dis 2004; 4(7): 445–455.

Nunes

Von Gottenberg

De Gouveia

et al . Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program. PLoS One 2011; 6: e27929.

10.

Jordano

Falco

Almrante

et al . Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38: 1623–1628.

11.

Harboe

Larsen

Ladelund

et al . Incidence and risk factors for invasive pneumococcal disease in HIV-infected and non-HIV-infected individuals before and after the introduction of combination antiretroviral therapy: persistent high risk among HIV-infected injecting drug users. Clin Infect Dis 2014; 59: 1168–1176.

12.

Rock

Sadlier

Fitzgerald

et al . Epidemiology of invasive pneumococcal disease and vaccine provision in a tertiary referral center. Eur J Clin Microbiol Infect Dis 2013; 32: 1135–1141.

13.

Grau

Pallares

Tabau

et al . Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165: 1533–1540.

14.

Moberley

Holden

Tathan

et al . Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1: Cd000422.

15.

Hausdorff

Bryant

Kloek

et al . The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis 2000; 30: 122–140.

16.

Hausdorff

Bryant

Paradiso

et al . Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000; 30: 100–121.

17.

Pendersen

Ostergaard

Sogaard

OS.

The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med 2011; 12: 323–333.

18.

Geretti

Brook

Cameron

et al . British HIV Association guidelines for immunization of HIV-infected adults 2015. HIV Med 2016; 17: S2–S81.

19.

Konkel-Parker

Vaccination of immunocompromised individuals: IDSA clinical practice guidelines. HIV Clin 2014; 26: 1–3.

20.

Black

Shinefield

Fireman

et al . Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19: 187–195.

21.

French

Gordon

Mwakujomo

et al . A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362: 812–822.

22.

Lesprit

Pedrono

Molina

et al . Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007; 21: 2425–2434.

23.

HPSC 2016. Summary immunisation uptake statistics, www.hpsc.ie/hpsc/A-Z/VaccinePreventable (accessed November 2018).

24.

Conway

Galvin

Coveney

et al . Deprivation as an outcome determinant in emergency medical admissions. QJM 2013; 106: 245–251.

25.

Tuite

Horgan

Mallon

et al . Patients accessing ambulatory care for HIV-infection: epidemiology and prevalence assessment. Ir Med J 2015; 108: 199–202.

26.

O’Connell

O’Rourke

Sweeney

et al . Factors associated with non-retention in HIV care in an era of widespread antiretroviral therapy. Int J STD AIDS 2017; 28: 679–684.

27.

Jackson

Janoff

EN.

Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008; 47: 1328–1338.

28.

Barry

Zetola

Keruly

et al . Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990–2003. AIDS 2006; 20: 437–444.

29.

Watera

Nakiyingi

Miiro

et al . 23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS 2004; 18: 1210–1213.

30.

Vickers

Fitzgerald

Murchan

et al . Serotype distribution of Streptococcus pneumoniae causing invasive disease in the Republic of Ireland. Epidemiol Infect 2011; 139: 783–790.

31.

Munier

De Lastours

Varon

et al . Invasive pneumococcal disease in HIV-infected adults in France from 2000 to 2011: antimicrobial susceptibility and implication of serotypes for vaccination. Infection 2013; 41: 663–668.